2. シグナル伝達
  3. Anti-infection
  4. SARS-CoV
  5. SARS-CoV Inhibitor

SARS-CoV Inhibitor

SARS-CoV Inhibitors (1025):

製品番号 製品名 製品効果 純度
  • HY-149320
    Acryl42-10 Inhibitor
    Acryl42-10 is a covalent inhibitor of the SARS-CoV-2 Nsp14 N7-Methyltransferase (IC50: 7 μM).
  • HY-P10976
    Spike Glycoprotein (1147-1162) Inhibitor
    Spike Glycoprotein (1147-1162) is a linear and broadly neutralizing peptide in the S2 protein of SARS-CoV-2. Spike Glycoprotein (1147-1162) is conserved across SARS-CoV, BatCoV RaTG13, SARS-CoV-2, and SARS-CoV-2 variants. Spike Glycoprotein (1147-1162)-targeting mAbs can neutralize both SARS-CoV-2 and SARS-CoV by preventing fusion between the virus and cell membrane. Spike Glycoprotein (1147-1162) can be used for universal vaccines against SARS-CoV-2 mutants research.
  • HY-183761
    Antiviral agent 86 Inhibitor
    Antiviral agent 86 is an anti-coronavirus agent. Antiviral agent 86 acts as a binder of coronavirus non-structural protein 15 (nsp15), with a Kd value of 67 μM against human targets. Antiviral agent 86 inhibits the replication of HCoV-229E and SARS-CoV-2. Antiviral agent 86 exerts inhibitory effects at the post-entry lifecycle stage of coronaviruses in host cells and inhibits the formation of viral double-stranded RNA (dsRNA). Antiviral agent 86 exhibits an additive antiviral effect when used in combination with GS-441524. Antiviral agent 86 can be used in studies related to coronavirus infections.
  • HY-148705
    Isomitomycin A Inhibitor
    Isomitomycin A is a potential inhibitor against SARS-CoV-2. Isomitomycin A targets to the hACE2 binding site of the modelled surface glycoprotein of SARS-CoV-2. Isomitomycin A can be used in studies of COVID-19.
  • HY-162474
    BZG2 Inhibitor
    BZG2 is an allosteric inhibitor for the SARS-CoV-2 main protease (Mpro), with an IC50 of 77 µM.
  • HY-N13245
    Milk Thistle Extract Inhibitor
    Milk Thistle Extract is the extract of Milk Thistle, with content of 80% Silymarin.
  • HY-155980
    SARS-CoV-2 3CLpro-IN-17 Inhibitor
    SARS-CoV-2 3CLpro-IN-17 (Compound 3h) is a selective SARS-CoV-2 3CLpro inhibitor (IC50s: 0.322 μM).
  • HY-170357
    SARS-CoV-2 3CLpro-IN-28 Inhibitor
    SARS-CoV-2 3CLpro-IN-28 (Compound 19) is an inhibitor for SARS-CoV-2 3CLpro with an IC50 of 0.018 μM.
  • HY-149317
    ZINC475239213 Inhibitor
    ZINC475239213 is an inhibitor of the SARS-CoV-2 Nsp14 N7-Methyltransferase (IC50: 20 μM).
  • HY-168441
    NCGC00537446 Inhibitor
    NCGC00537446 is a dual Nsp14 MTase/ExoN inhibitor. NCGC00537446 can be used for the research of SARS-CoV-2 replication and infection.
  • HY-150786
    PLP_Snyder530 Inhibitor
    PLP_Snyder530 is a potent papain-like protease (PLpro) inhibitor with an IC50 value of 6.4 μM. PLP_Snyder530 induces conformational changes in SARS-COV-2 papain-like protease, inhibiting SARS-CoV-2 replication. PLP_Snyder530 can be used for SARS-CoV-2 research.
  • HY-179334
    DMA-155 Inhibitor
    DMA-155 is an antiviral agent with binding activity against SARS-CoV-2 5'-terminal stem-loop RNAs, with affinities of 51.1 μM (SL1), 61.1 μM (SL4), 54.5 μM (SL5a), 66.9 μM (SL5b) and 48.6 μM (SL6), respectively. DMA-155 inhibits SARS-CoV-2 viral replication and reduces SARS-CoV-2 viral RNA levels. DMA-155 is applicable to the research of COVID-19.
  • HY-149314
    SARS-CoV-2-IN-47 Inhibitor
    SARS-CoV-2-IN-47 (Compound 13) is a SARS-CoV-2 inhibitor (IC50: 0.77 μM against Omicron BA.1, 0.93 μM against Delta strain). SARS-CoV-2-IN-47 can be used for antiviral research.
  • HY-W816575
    MDI-403 Inhibitor
    MDI-403 is a retinoic acid receptor (RAR) agonist with an EC50 value of less than 1 μM. MDI-403 exhibits significant antiviral activity against SARS-CoV-2, and can dose-dependently inhibit the expression of viral nucleoprotein (NP) and reduce the proportion of infected cells. MDI-403 mainly acts during the virus invasion stage. MDI-403 can be used in research on anti-SARS-CoV-2.
  • HY-155679
    SARS-CoV-2 nsp14-IN-4 Inhibitor
    SARS-CoV-2 nsp14-IN-4 (Compound 12q) is an inhibitor of SARS-CoV-2 nsp14 methyltransferase (IC50=19 nM). SARS-CoV-2 nsp14-IN-4 is non-cytotoxic and cell-permeable. SARS-CoV-2 nsp14-IN-4 is used in COVID-19 research.
  • HY-170767
    SARS-CoV-2-IN-109 Inhibitor
    SARS-CoV-2-IN-109 (compound 50) is an inhibitor targeting SARS-CoV with in vivo anti-infection activity. SARS-CoV-2-IN-109 targets the interaction between the SARS-CoV-2 Spike receptor-binding domain (RBD) and the human receptor angiotensin-converting enzyme 2 (ACE2) (EC50=26.5 μM), blocking the entry of SARS-CoV-2 into VeroE6 cells (EC50=17.0 μM). The CC50 of SARS-CoV-2-IN-109 for VeroE6 cells is >100 μM.
  • HY-149373
    Garcinone B Inhibitor
    Garcinone B, a xanthone derivative, is a nature product that could be isolated from the pericarp of Mangosteen. Garcinone B is a potent ACE2 and Mpro inhibitor. Garcinone B can be used in research of COVID-19.
  • HY-18219R
    Walrycin B (Standard) Inhibitor
    Walrycin B (Standard) is the analytical standard of Walrycin B. This product is intended for research and analytical applications. Walrycin B, an analogue of toxoflavin, is a potent SARS-CoV-2 3CLpro inhibitor with an IC50 of 0.26 μM. Walrycin B is a WalR response regulator inhibitor. Walrycin B has potent activity of inhibiting bacteria growth[1][2].
  • HY-151269
    SARS-CoV-2-IN-26 Inhibitor
    SARS-CoV-2-IN-23 is a two-armed diphosphate ester and medium length molecular tweezers. SARS-CoV-2-IN-23 exhibits antiviral activity with IC50s of 8.2 μM and 2.6 μM against SARS-CoV-2 activity and the spike pseudoparticle transduction, respectively. SARS-CoV-2-IN-23 induces liposomal membrane disruption with an EC50 value of 4.4 μM.
  • HY-168568
    SARS-CoV-2 Mpro-IN-28 Inhibitor
    SARS-CoV-2 Mpro-IN-28 (Compound 1K) is an inhibitor of SARS-CoV-2 Mpro with an EC50 value of 24 μM.